A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer

Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

1997 • 1,658 citations

Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer

2002 • 1,346 citations

Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer

1999 • 909 citations

Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument

1995 • 713 citations

Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.

1992 • 532 citations

Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.

1997 • 474 citations

Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS)

1993 • 293 citations

Topoisomerase I inhibitors: topotecan and irenotecan

1994 • 251 citations

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

2000 • 249 citations

Small Cell Lung Cancer*

2003 • 219 citations

Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.

1996 • 206 citations

Etoposide Plus Cisplatin With or Without the Combination of 4'-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study

2001 • 171 citations

Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.

1996 • 149 citations

Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells

1992 • 109 citations

Topoisomerase I inhibitors: topotecan and irinotecan.

1996 • 69 citations

Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients.

1999 • 68 citations

126 Evaluation of topotecan (Hycamtin™) in relapsed small cell lung cancer (SCLC). A multicentre phase II study

1997 • 63 citations

A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer

2000 • 27 citations

Novel Doublets in Extensive-Stage Small-Cell Lung Cancer: A Randomized Phase II Study of Topotecan Plus Cisplatin or Paclitaxel (CALGB 9430)

2002 • 27 citations

Phase II study of topotecan and paclitaxel for patients with previously untreated extensive stage small-cell lung cancer

2004 • 17 citations

A Phase I Trial of a 5-Day Schedule of Intravenous Topotecan and Etoposide in Previously Untreated Patients with Small-Cell Lung Cancer

2001 • 16 citations

222 Phase II trial of topotecan for small cell lung cancer (SCLC)

1997 • 5 citations

A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously in treated small cell lung cancer and extensive disease: Final results

2004 • 3 citations

A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously in treated small cell lung cancer and extensive disease: Final results

2004 • 2 citations